IMARC Group has recently released a report titled “Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the non-alcoholic fatty liver disease (NAFLD) market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Non-alcoholic fatty liver disease (NAFLD) represents a medical ailment that is distinguished by an excess of fat deposited in liver cells. It is mainly categorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver disease includes some of the common symptoms, such as pain in the upper right side of the abdomen, liver malfunction, fluid and swelling in the stomach and legs, a dull right upper quadrant abdominal discomfort, loss of weight, etc. A liver ultrasound scan or magnetic resonance imaging (MRI) can be utilized to identify metabolic derangements. A liver biopsy is then performed to assist in the diagnosis and differentiation of both kinds of NAFLD (including NAFL and NASH) from other types of liver disease. These specific diagnostics are followed by blood tests, which also contribute to validating the diagnosis.
Request a Free Sample Report: https://www.imarcgroup.com/non-alcoholic-fatty-liver-disease-market/requestsample
Market Trend:
The elevating prevalence of diabetes and obesity on account of the changing dietary patterns and sedentary lifestyles of consumers is primarily augmenting the non-alcoholic fatty liver disease (NAFLD) market. In addition to this, several technological advancements related to genetic testing for early and effective disease diagnosis are further propelling the market growth. Moreover, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness regarding the risk factors of liver-related disorders, including non-alcoholic fatty liver disease, which is positively influencing the market growth. Apart from this, the introduction of innovative imaging modalities for assessing fatty liver and fibrosis, such as magnetic resonance imaging-derived proton density fat fraction and MR elastography, is projected to fuel the growth of the non-alcoholic fatty liver disease (NAFLD) market in the coming years.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the non-alcoholic fatty liver disease (NAFLD) market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the non-alcoholic fatty liver disease (NAFLD) market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/non-alcoholic-fatty-liver-disease-market
Key Questions Answered in this Report:
- How has the non-alcoholic fatty liver disease (NAFLD) market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the non-alcoholic fatty liver disease (NAFLD) market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the non-alcoholic fatty liver disease (NAFLD) market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Browse the Latest Research Report:
Myasthenia Gravis Market Report 2023-2033
Heterozygous Familial Hypercholesterolemia Market Report 2023-2033
Pancreatic Cancer Market Report 2023-2033
AL Amyloidosis Market Report 2023-2033
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800